Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Sponsor seeks limits on mRNA therapies for infectious disease; subcommittee pauses debate after split testimony
Loading...
Summary
Representative Warren Magnuson introduced H4262, a bill to prohibit synthetic mRNA-based therapies for infectious diseases; medical groups, industry and patient-advocacy organizations strongly opposed the restriction and the subcommittee voted to adjourn debate for further stakeholder work.
Representative Warren Magnuson introduced House Bill H4262, which would prohibit administration of synthetic mRNA-based therapies for infectious diseases and impose professional licensing penalties, including a potential one-year suspension for intentionally administering such products for infectious disease purposes.
Magnuson framed the bill as a response to safety concerns raised during the COVID-19 pandemic, citing reporting systems and expert testimony and saying he was open to targeted carve-outs for noninfectious uses such as oncology or rare diseases. "We've seen that it's that it's not safe and effective and we are I believe needing as a state to make sure that people get that message," Magnuson said during sponsor remarks.
The measure prompted broad pushback from medical and research representatives. The American Cancer Society and the Melanoma Research Foundation warned that a ban could hinder experimental mRNA therapies in oncology; Beth Johnson, reading testimony for the melanoma group and the ACSCAN, said mRNA vaccines and therapeutics had potential to help cancer patients and that restricting access could be harmful to people with compromised immune systems.
Industry groups and life-science advocates also testified in opposition. Clay Alspach of the Alliance for mRNA Medicines described mRNA technology as transformative for cancer, rare diseases and infectious diseases and warned that a ban would disrupt research, jobs and U.S. competitiveness. "mRNA is one of the most transformative medical technologies of our age with proven safety and efficacy that is shaping the future of the treatment of cancer, rare diseases, and infectious diseases," Alspach said.
Clinicians gave mixed testimony but several practicing physicians urged caution about restricting clinical options. Dr. Danielle Sher, an internal-medicine physician at MUSC Health, told the subcommittee that COVID remains a risk for some patients and that clinicians and patients should retain the ability to weigh risks and benefits in the exam room.
After extended testimony — with scientists, patient-advocates and industry representatives on both sides — Representative Sessions moved to adjourn debate to allow policymakers and stakeholders to work together on language. The motion to adjourn debate carried on a recorded roll-call vote; committee members agreed to pause further floor action while staff and stakeholders attempt refinements.
